Biological therapy prior to repeat ileocolic resection in Crohn's disease can reduce the postoperative complication rate.
Crohn’s disease
Postoperative complications
Repeat ileocolic resection
Journal
Techniques in coloproctology
ISSN: 1128-045X
Titre abrégé: Tech Coloproctol
Pays: Italy
ID NLM: 9613614
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
22
03
2022
accepted:
02
09
2022
pubmed:
30
9
2022
medline:
15
3
2023
entrez:
29
9
2022
Statut:
ppublish
Résumé
The aim of this study was to assess the effect of preoperative biologic therapy on the surgical outcome of Crohn's disease (CD) patients undergoing repeat ileocolic resection. This was a retrospective analysis of all CD patients who underwent repeat ileocolic resection at Cleveland Clinic Florida between January 2011 and April 2021. Patients were divided into two groups: treatment biologic therapy prior to surgery and controls. Sixty-five patients (31males, median age 54 [range 23-82] years) were included in the study. Twenty nine (44.6%) were treated with biologic therapy prior to repeat ileocolic resection. No demographic differences were found between the biologic therapy and control groups. In addition, no differences were found in mean time from index ileocolic resection (p = 0.9), indication for surgery (p = 0.11), and preoperative albumin (p = 0.69). The majority of patients (57; 87.7%) were operated on laparoscopically, and mean overall operation time was 225 (SD 49.27) min. Overall, the postoperative complication rate was 43.1% (28 patients) and median length of stay was 5 (range 2-21) days. Postoperative complications were more common in the control group, compared to the biologic therapy group (55.6 vs 27.5%; p = 0.04). Conversion rate (35.7 vs 20.7%; p = 0.24), operation time (223 vs 219 min; p = 0.75), length of stay (5.2 vs 5.9 days; p = 0.4), and readmission (16.6 vs 11.1%; p = 0.72) were similar between the two groups. Multivariate analysis of risk factors for postoperative complications showed that biologic treatment was correlated with a lower risk (HR -0.28, CI 95% -0.5596 to -0.01898, p = 0.03). Patients treated with biologic therapy for CD who underwent repeat ileocolic resection had fewer postoperative complications.
Sections du résumé
BACKGROUND
The aim of this study was to assess the effect of preoperative biologic therapy on the surgical outcome of Crohn's disease (CD) patients undergoing repeat ileocolic resection.
METHODS
This was a retrospective analysis of all CD patients who underwent repeat ileocolic resection at Cleveland Clinic Florida between January 2011 and April 2021. Patients were divided into two groups: treatment biologic therapy prior to surgery and controls.
RESULTS
Sixty-five patients (31males, median age 54 [range 23-82] years) were included in the study. Twenty nine (44.6%) were treated with biologic therapy prior to repeat ileocolic resection. No demographic differences were found between the biologic therapy and control groups. In addition, no differences were found in mean time from index ileocolic resection (p = 0.9), indication for surgery (p = 0.11), and preoperative albumin (p = 0.69). The majority of patients (57; 87.7%) were operated on laparoscopically, and mean overall operation time was 225 (SD 49.27) min. Overall, the postoperative complication rate was 43.1% (28 patients) and median length of stay was 5 (range 2-21) days. Postoperative complications were more common in the control group, compared to the biologic therapy group (55.6 vs 27.5%; p = 0.04). Conversion rate (35.7 vs 20.7%; p = 0.24), operation time (223 vs 219 min; p = 0.75), length of stay (5.2 vs 5.9 days; p = 0.4), and readmission (16.6 vs 11.1%; p = 0.72) were similar between the two groups. Multivariate analysis of risk factors for postoperative complications showed that biologic treatment was correlated with a lower risk (HR -0.28, CI 95% -0.5596 to -0.01898, p = 0.03).
CONCLUSIONS
Patients treated with biologic therapy for CD who underwent repeat ileocolic resection had fewer postoperative complications.
Identifiants
pubmed: 36175722
doi: 10.1007/s10151-022-02702-0
pii: 10.1007/s10151-022-02702-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
291-296Informations de copyright
© 2022. Springer Nature Switzerland AG.
Références
Ferrari L, Krane MK, Fichera A (2016) Inflammatory bowel disease surgery in the biologic era. World J Gastrointest Surg 8:363–370
doi: 10.4240/wjgs.v8.i5.363
pubmed: 27231514
pmcid: 4872064
Gardiner KR, Dasari BV (2007) Operative management of small bowel Crohn’s disease. Surg Clin North Am 87:587–610
doi: 10.1016/j.suc.2007.03.011
pubmed: 17560414
Lewis RT, Maron DJ (2010) Efficacy and complications of surgery for Crohn’s disease. Gastroenterol Hepatol (NY) 6:587–596
Grass F, Pache B, Martin D, Hahnloser D, Demartines N, Hubner M (2017) Preoperative nutritional conditioning of Crohn’s patients-systematic review of current evidence and practice. Nutrients 9:562
doi: 10.3390/nu9060562
pubmed: 28587182
pmcid: 5490541
Nguyen GC, Elnahas A, Jackson TD (2014) The impact of preoperative steroid use on short-term outcomes following surgery for inflammatory bowel disease. J Crohns Colitis 8:1661–1667
doi: 10.1016/j.crohns.2014.07.007
pubmed: 25107847
Yamamoto T, Allan RN, Keighley MR (2000) Risk factors for intra-abdominal sepsis after surgery in Crohn’s disease. Dis Colon Rectum 43:1141–1145
doi: 10.1007/BF02236563
pubmed: 10950014
Ali T, Yun L, Rubin DT (2012) Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. World J Gastroenterol 18:197–204
doi: 10.3748/wjg.v18.i3.197
pubmed: 22294822
pmcid: 3261536
Kopylov U, Ben-Horin S, Zmora O, Eliakim R, Katz LH (2012) Anti-tumor necrosis factor and postoperative complications in Crohn’s disease: systematic review and meta-analysis. Inflamm Bowel Dis 18:2404–2413
doi: 10.1002/ibd.22954
pubmed: 22467533
Yung DE, Horesh N, Lightner AL et al (2018) Systematic review and meta-analysis: vedolizumab and postoperative complications in inflammatory bowel disease. Inflamm Bowel Dis 24:2327–2338
doi: 10.1093/ibd/izy156
pubmed: 29788385
Carmichael H, Peyser D, Baratta VM et al (2021) The role of laparoscopic surgery in repeat ileocolic resection for Crohn’s disease. Colorectal Dis 23:2075–2084
doi: 10.1111/codi.15675
pubmed: 33851498
Celentano V, Sagias F, Flashman KG, Conti J, Khan J (2019) Laparoscopic redo ileocolic resection for Crohn’s disease in patients with previous multiple laparotomies. Scand J Surg 108:42–48
doi: 10.1177/1457496918772370
pubmed: 29742985
Kalman TD, Everhov AH, Nordenvall C et al (2020) Decrease in primary but not in secondary abdominal surgery for Crohn’s disease: nationwide cohort study, 1990–2014. Br J Surg 107:1529–1538
doi: 10.1002/bjs.11659
pubmed: 32452553
Riss S, Schuster I, Papay P, Mittlböck M, Stift A (2013) Repeat intestinal resections increase the risk of recurrence of Crohn’s disease. Dis Colon Rectum 56:881–887
doi: 10.1097/DCR.0b013e31828cb80c
pubmed: 23739195
Colombo F, Frontali A, Baldi C et al (2022) Repeated surgery for recurrent Crohn’s disease: does the outcome keep worsening operation after operation? A comparative study of 1224 consecutive procedures. Updates Surg 74:73–80
doi: 10.1007/s13304-021-01187-0
pubmed: 34725796
Leinicke JA, Dietz DW (2019) Reoperative surgery in complex Crohn’s disease. Clin Colon Rectal Surg 2:291–299
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213
doi: 10.1097/01.sla.0000133083.54934.ae
pubmed: 15273542
pmcid: 1360123
Samaan M, Campbell S, Cunningham G, Tamilarasan AG, Irving PM, McCartney S (2019) Biologic therapies for Crohn’s disease: optimising the old and maximising the new. F1000Res 8:F1000 Faculty Rev-1210. https://doi.org/10.12688/f1000research.18902.1 .
Binion DG (2010) Biologic therapies for Crohn’s disease: update from the 2009 ACG meeting. Gastroenterol Hepatol (N Y) 6(1):4–16
pubmed: 20567545
Lauro R, Mannino F, Irrera N, Squadrito F, Altavilla D, Squadrito G, Pallio G, Bitto A (2021) Pharmacogenetics of biological agents used in inflammatory bowel disease: a systematic review. Biomedicines 9:1748
doi: 10.3390/biomedicines9121748
pubmed: 34944563
pmcid: 8699014
Nadpara N, Reichenbach ZW, Ehrlich AC, Friedenberg F (2020) Current status of medical therapy for inflammatory bowel disease: the wealth of medications. Dig Dis Sci 65:2769–2779
doi: 10.1007/s10620-020-06471-4
pubmed: 32661765
Colombel JF, Loftus EV Jr, Tremaine WJ et al (2004) Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 99:878–883
doi: 10.1111/j.1572-0241.2004.04148.x
pubmed: 15128354
Ahmed Ali U, Martin ST, Rao AD, Kiran RP (2014) Impact of preoperative immunosuppressive agents on postoperative outcomes in Crohn’s disease. Dis Colon Rectum 57:663–674
doi: 10.1097/DCR.0000000000000099
pubmed: 24819109
White EC, Melmed GY, Vasiliauskas E et al (2012) Does preoperative immunosuppression influence unplanned hospital readmission after surgery in patients with Crohn’s disease? Dis Colon Rectum 55:563–568
doi: 10.1097/DCR.0b013e3182468961
pubmed: 22513435
Lau C, Dubinsky M, Melmed G et al (2015) The impact of preoperative serum anti-TNFalpha therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg 261(3):487–496
doi: 10.1097/SLA.0000000000000757
pubmed: 24950263
Nasir BS, Dozois EJ, Cima RR et al (2010) Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn’s disease. J Gastrointest Surg 14:1859–1865
doi: 10.1007/s11605-010-1341-5
pubmed: 20872084
Marchal L, D’Haens G, Van Assche G et al (2004) The risk of post-operative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther 19:749–754
doi: 10.1111/j.1365-2036.2004.01904.x
pubmed: 15043515
Cohen BL, Fleshner P, Kane SV et al (2019) 415a–anti-tumor necrosis factor therapy is not associated with post-operative infection: results from prospective cohort of ulcerative colitis and Crohn’s disease patients undergoing surgery to identify risk factors for postoperative infection I (Puccini). Gastroenterology 156(6):S80
doi: 10.1016/S0016-5085(19)36987-2
Yang ZP, Hong L, Wu Q, Wu KC, Fan DM (2014) Preoperative infliximab use and postoperative complications in Crohn’s disease: a systematic review and meta-analysis. Int J Surg 12:224–230
doi: 10.1016/j.ijsu.2013.12.015
pubmed: 24394691
Garg R, Mohan BP, Ponnada S, Regueiro M, Lightner AL, Click B (2021) Postoperative outcomes after preoperative ustekinumab exposure in patients with Crohn’s disease: a systematic review and meta-analysis. Ann Gastroenterol 34:691–698
pubmed: 34475740
pmcid: 8375651
Johnston WF, Stafford C, Francone TD et al (2017) What is the risk of anastomotic leak after repeat intestinal resection in patients with Crohn’s disease? Dis Colon Rectum 60:1299–1306
doi: 10.1097/DCR.0000000000000946
pubmed: 29112566
Brouquet A, Blanc B, Bretagnol F, Valleur P, Bouhnik Y, Panis Y (2010) Surgery for intestinal Crohn’s disease recurrence. Surgery 148:936–946
doi: 10.1016/j.surg.2010.02.001
pubmed: 20363010
Collaborative SCSoCsDS (2021) National variations in perioperative assessment and surgical management of Crohn’s disease: a multicentre study. Colorectal Dis 23:94–104
doi: 10.1111/codi.15334